Stifel analyst Paul Matteis maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and raises the price target from $215 to $295.
Stifel Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $295
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.